Regulatory glossary

510(k) Transfer of Ownership: What Changes Hands in a Device Deal

When a cleared device is sold, the 510(k) clearance goes with it. The buyer becomes the 510(k) holder and inherits a regulatory position it did not build, usually without the people who built it.

The mechanics surprise most first-time acquirers, because there is far less paperwork than they expect and one deadline they tend to miss.

There is no transfer form

FDA does not require a specific form, a notice letter, or its approval to transfer a 510(k). Unlike other marketing authorisations, ownership moves as a matter of private contract between the parties.

The contrast with drugs is sharp. Changing the owner of an NDA or ANDA is governed by 21 CFR 314.72, which requires the former owner to notify FDA and the new owner to submit an application information amendment. Devices have no equivalent step.

This is why device deals close with the regulatory position undocumented. Nobody had to file anything, so nobody assembled the file.

What you do have to do

Registration and listing, within 30 days. The new holder must list the device under its own establishment registration in FURLS, through the Device Registration and Listing Module. This is the deadline that gets missed, because it is an operational task rather than a deal task, and it lands after the lawyers have left.

Labelling. Labels and labelling carry the name and place of business of the manufacturer, packer or distributor. A change of owner usually makes those wrong, and correcting them is not always a trivial print change when the label is referenced in the cleared submission.

One holder at a time. Only a single entity can hold a given 510(k). The holder is the party introducing the device into interstate commerce. Splitting a clearance between two entities is not available.

When the deal triggers a new 510(k)

An ownership change on its own does not. A new submission is required if the device is significantly changed or modified in a way that affects safety or effectiveness, on the ordinary 510(k) test, or where the new holder would be introducing the device into commercial distribution for the first time.

In practice the risk is a buyer who acquires a clearance and then changes the manufacturing site, the sterilisation method or a material, and treats it as an internal decision because no FDA filing accompanied the purchase.

What the acquirer actually inherits

The clearance is the visible asset. The obligations behind it are the liability:

• The design history file and the design controls that support the clearance.
• The risk management file under ISO 14971, which has to stay current.
• Complaint handling, MDR reporting and post-market surveillance for devices already in the field, including units the seller shipped.
• Any open corrective actions, 483 observations or Warning Letter commitments attached to the site or the product.

A carve-out is the difficult case. The product leaves a company whose central quality and regulatory function stays behind, so the file arrives without the system that maintained it.